

# Giulia Pasello

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6578549/giulia-pasello-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97  
papers

1,683  
citations

19  
h-index

38  
g-index

145  
ext. papers

2,384  
ext. citations

4.5  
avg, IF

4.64  
L-index

#	Paper	IF	Citations
97	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 914-922	21.7	328
96	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 1655-1669	21.7	215
95	Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 342-349	2.2	70
94	Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. <i>Oncologist</i> , <b>2019</b> , 24, 1128-1136	5.7	68
93	Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1258-1265	10.3	51
92	Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 326-32	7.5	46
91	The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. <i>European Journal of Cancer</i> , <b>2018</b> , 101, 191-200	7.5	44
90	18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy. <i>Nuclear Medicine Communications</i> , <b>2019</b> , 40, 802-807	1.6	43
89	Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1528-1534	10.3	42
88	Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges <b>2019</b> , 7, 205		41
87	Effects of sulfonylureas on tumor growth: a review of the literature. <i>Oncologist</i> , <b>2013</b> , 18, 1118-25	5.7	38
86	Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 87, 102031	14.4	37
85	Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 97, 220-30	7	35
84	Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. <i>Anticancer Research</i> , <b>2010</b> , 30, 5121-8	2.3	35
83	Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 220-6	8.7	28
82	Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 81-91	8.7	23
81	DNA copy number alterations correlate with survival of esophageal adenocarcinoma patients. <i>Modern Pathology</i> , <b>2009</b> , 22, 58-65	9.8	22

80	Molecular targets in malignant pleural mesothelioma treatment. <i>Current Drug Targets</i> , <b>2009</b> , 10, 1235-44		22
79	LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	20
78	An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 10-7	14.4	18
77	Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 1438-1447	21.7	18
76	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). <i>Cancer Treatment Reviews</i> , <b>2018</b> , 71, 76-87	14.4	17
75	Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 740	5.3	14
74	Results of surgical resection after induction chemoradiation for Pancoast tumours □ <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2015</b> , 20, 805-11; discussion 811-2	1.8	14
73	Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection. <i>Interactive Cardiovascular and Thoracic Surgery</i> , <b>2014</b> , 19, 256-62; discussion 262	1.8	14
72	DNA copy number profile discriminates between esophageal adenocarcinoma and squamous cell carcinoma and represents an independent prognostic parameter in esophageal adenocarcinoma. <i>Cancer Letters</i> , <b>2011</b> , 310, 84-93	9.9	14
71	Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7527-7527	2.2	14
70	Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. <i>Oncotarget</i> , <b>2017</b> , 8, 32626-32638	3.3	14
69	Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1750-1761	8.9	14
68	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 202-220	4.4	13
67	Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab. <i>European Journal of Dermatology</i> , <b>2017</b> , 27, 205-208	0.8	12
66	Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience. <i>Oncologist</i> , <b>2020</b> , 25, e1996-e2005	5.7	11
65	A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, e63-e64	8.9	11
64	COPD-related adenocarcinoma presents low aggressiveness morphological and molecular features compared to smoker tumours. <i>Lung Cancer</i> , <b>2014</b> , 86, 311-7	5.9	11
63	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. <i>Cancers</i> , <b>2020</b> , 12,	6.6	11

62	RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e811-e814	4.9	10
61	Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience. <i>Lung Cancer</i> , <b>2011</b> , 73, 351-5	5.9	10
60	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 1-14.e3	4.9	10
59	Second and third line treatment in advanced non-small cell lung cancer. <i>Discovery Medicine</i> , <b>2009</b> , 8, 204-215	9.5	10
58	PET/CT and the Response to Immunotherapy in Lung Cancer. <i>Current Radiopharmaceuticals</i> , <b>2020</b> , 13, 177-184	1.8	9
57	Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists. <i>Oncotarget</i> , <b>2017</b> , 8, 44232-44241	3.3	9
56	MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data. <i>Oncotarget</i> , <b>2015</b> , 6, 42053-66	3.3	9
55	Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 138, 87-103	7	8
54	Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 1008-1017	8.9	8
53	Metabolic rewiring and redox alterations in malignant pleural mesothelioma. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 52-61	8.7	8
52	Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced non-small cell lung cancer (aNSCLC): A prospective study. <i>Annals of Oncology</i> , <b>2018</b> , 29, viii649	10.3	8
51	Does Induction Therapy Increase Anastomotic Complications in Bronchial Sleeve Resections?. <i>World Journal of Surgery</i> , <b>2019</b> , 43, 1385-1392	3.3	7
50	Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature. <i>American Journal of Case Reports</i> , <b>2015</b> , 16, 782-9	1.3	7
49	Second and third line treatment in non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 71, 117-26	7	7
48	Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 128, 19-29	7	7
47	Immunohistochemical neuroendocrine marker expression in primary pulmonary NUT carcinoma: a diagnostic pitfall. <i>Histopathology</i> , <b>2020</b> , 77, 508-510	7.3	6
46	Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization. <i>Oncotarget</i> , <b>2016</b> , 7, 25050-63	3.3	6
45	A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Diagnostics</i> , <b>2020</b> , 10,	3.8	6

44	Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, e5-e7	8.9	6
43	Preoperative concomitant chemo-radiotherapy in superior sulcus tumour: A mono-institutional experience. <i>Lung Cancer</i> , <b>2010</b> , 68, 228-33	5.9	5
42	P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 653497	5.3	5
41	Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature. <i>Experimental and Therapeutic Medicine</i> , <b>2016</b> , 11, 197-200	2.1	5
40	Immune checkpoint inhibitors in mesothelioma: a turning point. <i>Lancet, The</i> , <b>2021</b> , 397, 348-349	4.0	5
39	Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4
38	Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 564915	5.3	4
37	SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 1810-1821	4.4	4
36	Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 361-370.e3	4.9	4
35	Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial. <i>ESMO Open</i> , <b>2021</b> , 6, 100051	6	4
34	How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 669786	5.3	4
33	Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 13-20	3.2	4
32	Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. <i>British Journal of Cancer</i> , <b>2022</b> ,	8.7	4
31	Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma. <i>Oncology Research and Treatment</i> , <b>2017</b> , 40, 364-369	2.8	3
30	From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for -Positive Non-Small Cell Lung Cancer (MOST Study). <i>Oncologist</i> , <b>2019</b> , 24, e318-e326	5.7	3
29	The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 169, 103561	7	3
28	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
27	Relapse Patterns and Tailored Treatment Strategies for Malignant Pleural Mesothelioma Recurrence after Multimodality Therapy. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3

26	Immunotherapy in malignant pleural mesothelioma: a review of literature data. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 2988-3000	4.4	3
25	First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. <i>Oncologist</i> , <b>2021</b> ,	5.7	3
24	1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM). <i>Annals of Oncology</i> , <b>2020</b> , 31, S1078	10.3	2
23	1939P Potential role of longitudinal plasma next generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) experiencing hyperprogression (HPD) and early death (ED) during treatment with immune checkpoint inhibitors (ICIs). <i>Annals of Oncology</i> , <b>2020</b> , 31, S1096	10.3	2
22	Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2013</b> , 44, 104-10	3	2
21	Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario.. <i>ESMO Open</i> , <b>2022</b> , 7, 100406	6	2
20	Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare Histological Subtypes (CHANCE trial). <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920915983	5.4	2
19	Diagnostic Challenges in Epithelioid Pleural Mesothelioma: Case Series with Support from Electron Microscopy. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	2
18	Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 163, 103378	7	2
17	Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 3671-81	4.4	2
16	Lobectomy With Artery Reconstruction and Pneumonectomy for Non-Small Cell Lung Cancer: A Propensity Score Weighting Study. <i>Annals of Thoracic Surgery</i> , <b>2021</b> , 112, 1805-1813	2.7	2
15	Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 191-198	4.9	1
14	A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERA-VOLT registry.. <i>Journal of Thoracic Oncology</i> , <b>2022</b> ,	8.9	1
13	Non-Small-Cell Lung Cancer: Real-World Cost Consequence Analysis. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e1085-e1093	2.3	1
12	Computed Tomography and Spirometry Can Predict Unresectability in Malignant Pleural Mesothelioma. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
11	SMO mutations confer poor prognosis in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 1940-1951	4.4	0
10	Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in -Mutated Non-small Cell Lung Cancer: A Case Report. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 570921	4.9	0
9	Real-world data on treatment outcomes in -mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. <i>Future Oncology</i> , <b>2021</b> , 17, 2513-2527	3.6	0

8	Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification. <i>Cytokine</i> , <b>2021</b> , 146, 155622	4	○
7	SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 840783	5.3	○
6	Monitoring advanced non-small cell lung cancer (NSCLC) through plasma genotyping during systemic treatment: KRAS-mutated (m) cohort results.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e24074-e24074	2.2	○
5	Targeted Therapies in Mesothelioma <b>2019</b> , 243-259		
4	Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e20612-e20612	2.2	
3	Clinicopathologic features of patients with malignant mesothelioma in a multicenter, retrospective study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e18544-e18544	2.2	
2	Clinicopathological features of patients with malignant mesothelioma in a multicenter, retrospective study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e12651-e12651	2.2	
1	Malignant pleural mesothelioma (MPM) in elderly patients: A multicenter survey.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7082-7082	2.2	